

Proven Utility

REVEAL	PAH Risk Score			
WHO Group I Subgroup	AFAH-CTD +1	AFAH-PPH +2	PPAH +2	<input type="text"/>
Demographics & Comorbidities	Renal Insufficiency +1	Males Age>60yrs +2		<input type="text"/>
NYHA/WHO Functional Class	I -2	III +1	IV +2	<input type="text"/>
Vital Signs	SBP<110 mm Hg +1	HR<92 BPM +1		<input type="text"/>
6-Minute Walk Test	>440 m -1	<165 m +1		<input type="text"/>
BNP	<50 pg/mL -2	>180 pg/mL +1		<input type="text"/>
Echocardiogram	Pericardial Effusion +1			<input type="text"/>
Pulmonary Function Test	% pred. DLco>80 -1	% pred. DLco<32 +1		<input type="text"/>
Right Heart Catheterization	mRAP>20 mm Hg within 1 yr +1	PVR>32 Wood units +2		<input type="text"/>
SUM OF ABOVE				
				+ 6
= RISK SCORE				<input type="text"/>

About Us:

Led by Allegheny Cardiovascular Research Institute and sponsored by NIH/NHLBI, **PHORA** is a global collaboration between:

FDA ♦ Actelion ♦ Bayer ♦
 United Therapeutics ♦
 Cornell University ♦
 University of Pittsburgh ♦
 International PAH experts




Pulmonary Hypertension
Outcomes Risk Assessment




Pulmonary hypertension prognostic and clinical decision support tool for clinicians

Advanced Analysis



For more information about the **PHORA** research project, see our website <http://myphora.org> or contact us at phora@ahn.org

Funded by:
NIH/NHLBI HL134673



*PHORA is not available to patients and is only for use by clinicians.

What is PHORA?


Over the past decade, new therapies have emerged to improve survival and quality of life, yet Pulmonary Arterial Hypertension (PAH) prognosis remains grim. To improve outcome, effective treatment requires early detection and selection of the optimal therapy for the individual patient.



myPHORA (Pulmonary Hypertension Outcomes Risk Assessment) is an investigational clinical decision support system for clinicians who treat patients with PAH.

myPHORA utilizes prognostic models for key patient outcomes. Using machine learning, the **PHORA** model is derived from contemporary literature, expert input, and clinical trial data.

PHORA App



- ✓ Side-by-side comparison of REVEAL 2.0, ERS and PHORA calculators
- ✓ Visualization of the 2015 ESC/ERS Treatment Guidelines for risk score
- ✓ What-if analysis

What is being evaluated?

myPHORA is a prototype decision support system, designed to improve the stratification and management of PAH patients using a user-friendly design and prognostic models. Clinician user feedback will provide insight into the unmet needs and application usability to guide application development.

Who can participate?

Clinicians who treat patients with PAH are invited to participate.

What will my participation involve?

The myPHORA demo and interview will take place during the 2018 PHA Conference Research Room hours. We may audiotape conversations for note taking purposes. Interviews and demo should take approximately 15 minutes.

- You will be asked to describe how you usually diagnose and treat your PAH patients, including the risk stratification tools you currently employ
- You will be shown the myPHORA prototype on a tablet or laptop and be invited to test it
- You will be asked to comment on the features, performance, and visualization
- You may be asked what other information would be useful in the myPHORA application, and what additional features would be clinically relevant.
- You may be asked how you might use a tool like PHORA in your clinical practice